Ariad Pharmaceuticals has announced the discontinuation of the Phase 3 trial of its chronic myeloid leukemia drug, Iclusig, due to reports of increased blood clots in patients. Ariad and the FDA mutually agreed that the trial should be terminated, a decision which came a week after the agency placed the drug on partial clinical hold. The company said that the decision was made in the interest of patient safety based on recent assessment of data in the clinical trial.

Related Summaries